Evidence map›Paper›PMID 38904421›Full record

ReviewJournal of environmental science and health. Part C, Toxicology and carcinogenesis2024

Metabolism and liver toxicity of cannabidiol.

Si Chen, Yuxi Li, Xilin Li, Qiangen Wu, Montserrat Puig, Frederic Moulin, Jeremy Gingrich, Lei Guo

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of environmental science and health. Part C, Toxicology and carcinogenesis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. ComparativeFrontiers in toxicology · 2026
    Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Utilization of Cannabidiol in Post-Organ-Transplant Care.International journal of molecular sciences · 2025
    Review
  11. Article
  12. Review of black cohosh-induced toxicity and adverse clinical effects.Journal of environmental science and health. Part C, Toxicology and carcinogenesis · 2025
    Review
  13. Potential anticancer effects and toxicity of flavones luteolin and apigeninJournal of environmental science and health. Part C, Toxicology and carcinogenesis · 2025
    Review
  14. Article
  15. The effects of cannabinoids on the kidney.Acta physiologica (Oxford, England) · 2024
    Review
  16. Inter-strain variability in responses to a single administration of the cannabidiol-rich cannabis extract in mice.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2024
    Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Si ChenDivision of Biochemical Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration (FDA), Jefferson, Arkansas, USA.
Yuxi LiDivision of Biochemical Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration (FDA), Jefferson, Arkansas, USA.
Xilin LiDivision of Genetic and Molecular Toxicology, National Center for Toxicological Research, U.S. FDA, Jefferson, Arkansas, USA.
Qiangen WuDivision of Biochemical Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration (FDA), Jefferson, Arkansas, USA.
Montserrat PuigDivision of Biotechnology Review and Research III, Office of Biotechnology Products, Center for Drug Evaluation and Research, U.S. FDA, Silver Spring, Maryland, USA.
Frederic MoulinDivision of Hepatology and Nutrition, Office of New Drugs, Center for Drug Evaluation and Research, U.S. FDA, Silver Spring, Maryland, USA.
Jeremy GingrichOffice of Food Additive Safety, Center for Food Safety and Applied Nutrition, U.S. FDA, College Park, Maryland, USA.
Lei GuoDivision of Biochemical Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration (FDA), Jefferson, Arkansas, USA.ORCID 0000-0002-0402-4152

Funding

Intramural FDA HHS FD999999
6 · The paper itself

Abstract

Increasing public interest has resulted in the widespread use of non-pharmaceutical cannabidiol (CBD) products. The sales of CBD products continue to rise, accompanied by concerns regarding unsubstantiated benefits, lack of product quality control, and potential health risks. Both animal and human studies have revealed a spectrum of toxicological effects linked to the use of CBD. Adverse effects related to exposure of humans to CBD include changes in appetite, gastrointestinal discomfort, fatigue, and elevated liver aminotransferase enzymes. Animal studies reported changes in organ weight, reproduction, liver function, and the immune system. This review centers on human-derived data, including clinical studies and

Indexed as

CannabidiolLiverAnimalsChemical and Drug Induced Liver InjuryHumansCannabidiolCannabidiolCBDliver toxicitymetabolismtoxicity

Identifiers

PMID38904421
PMCPMC11404724

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.